Current Research Studies
A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled Study (Part 1) and Open-Label Extension (Part 2) to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich’s Ataxia Aged 2 to < 16 Years
Biogen _ BRAVE_FA
What is the goal of the study?
Is a Randomized Clinical Trial study that will be conducted to evaluate the effectiveness of omaveloxolone by comparing the omaveloxolone treatment group with a placebo group. The active treatment provides the possibility of benefit based on the efficacy of omaveloxolone previously demonstrated in other studies.
Who can participate in the study?
Please contact the study team listed below to learn more.